These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37298854)

  • 41. Activation of Escherichia coli UDP-3-O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase by Fe2+ yields a more efficient enzyme with altered ligand affinity.
    Hernick M; Gattis SG; Penner-Hahn JE; Fierke CA
    Biochemistry; 2010 Mar; 49(10):2246-55. PubMed ID: 20136146
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis.
    Whittington DA; Rusche KM; Shin H; Fierke CA; Christianson DW
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8146-50. PubMed ID: 12819349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.
    Tomaras AP; McPherson CJ; Kuhn M; Carifa A; Mullins L; George D; Desbonnet C; Eidem TM; Montgomery JI; Brown MF; Reilly U; Miller AA; O'Donnell JP
    mBio; 2014 Sep; 5(5):e01551-14. PubMed ID: 25271285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Complex Structure of Protein AaLpxC from
    Fan S; Li D; Yan M; Feng X; Lv G; Wu G; Jin Y; Wang Y; Yang Z
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33800069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
    Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
    J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis and biological evaluation of enantiomerically pure glyceric acid derivatives as LpxC inhibitors.
    Tangherlini G; Torregrossa T; Agoglitta O; Köhler J; Melesina J; Sippl W; Holl R
    Bioorg Med Chem; 2016 Mar; 24(5):1032-44. PubMed ID: 26827141
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure of the metal-dependent deacetylase LpxC from Yersinia enterocolitica complexed with the potent inhibitor CHIR-090 .
    Cole KE; Gattis SG; Angell HD; Fierke CA; Christianson DW
    Biochemistry; 2011 Jan; 50(2):258-65. PubMed ID: 21171638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens.
    Zhao J; Cochrane CS; Najeeb J; Gooden D; Sciandra C; Fan P; Lemaitre N; Newns K; Nicholas RA; Guan Z; Thaden JT; Fowler VG; Spasojevic I; Sebbane F; Toone EJ; Duncan C; Gammans R; Zhou P
    Sci Transl Med; 2023 Aug; 15(708):eadf5668. PubMed ID: 37556556
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
    Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
    Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Crystal structure of A. aeolicus LpxC with bound product suggests alternate deacetylation mechanism.
    Miller MD; Gao N; Ross PL; Olivier NB
    Proteins; 2015 Sep; 83(9):1706-19. PubMed ID: 26177919
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis, biological evaluation, and molecular docking studies of aldotetronic acid-based LpxC inhibitors.
    Wimmer S; Hoff K; Martin B; Grewer M; Denni L; Lascorz Massanet R; Raimondi MV; Bülbül EF; Melesina J; Hotop SK; Haupenthal J; Rohde H; Heisig P; Hirsch AKH; Brönstrup M; Sippl W; Holl R
    Bioorg Chem; 2023 Feb; 131():106331. PubMed ID: 36587505
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of human challenge and MDR strains of Neisseria gonorrhoeae with LpxC inhibitors.
    John CM; Feng D; Jarvis GA
    J Antimicrob Chemother; 2018 Aug; 73(8):2064-2071. PubMed ID: 29726994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC.
    Barb AW; Leavy TM; Robins LI; Guan Z; Six DA; Zhou P; Hangauer MJ; Bertozzi CR; Raetz CR
    Biochemistry; 2009 Apr; 48(14):3068-77. PubMed ID: 19256534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structures of the Peptidoglycan N-Acetylglucosamine Deacetylase Bc1974 and Its Complexes with Zinc Metalloenzyme Inhibitors.
    Giastas P; Andreou A; Papakyriakou A; Koutsioulis D; Balomenou S; Tzartos SJ; Bouriotis V; Eliopoulos EE
    Biochemistry; 2018 Feb; 57(5):753-763. PubMed ID: 29257674
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-throughput catch-and-release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: in vitro enzyme inhibition and antibacterial properties.
    Pirrung MC; Tumey LN; McClerren AL; Raetz CR
    J Am Chem Soc; 2003 Feb; 125(6):1575-86. PubMed ID: 12568618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532.
    Ushiyama F; Takashima H; Matsuda Y; Ogata Y; Sasamoto N; Kurimoto-Tsuruta R; Ueki K; Tanaka-Yamamoto N; Endo M; Mima M; Fujita K; Takata I; Tsuji S; Yamashita H; Okumura H; Otake K; Sugiyama H
    Bioorg Med Chem; 2021 Jan; 30():115964. PubMed ID: 33385955
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design.
    Lee CJ; Liang X; Chen X; Zeng D; Joo SH; Chung HS; Barb AW; Swanson SM; Nicholas RA; Li Y; Toone EJ; Raetz CR; Zhou P
    Chem Biol; 2011 Jan; 18(1):38-47. PubMed ID: 21167751
    [TBL] [Abstract][Full Text] [Related]  

  • 58. UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase functions through a general acid-base catalyst pair mechanism.
    Hernick M; Gennadios HA; Whittington DA; Rusche KM; Christianson DW; Fierke CA
    J Biol Chem; 2005 Apr; 280(17):16969-78. PubMed ID: 15705580
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis, biological evaluation, and molecular docking studies of deoxygenated C-glycosides as LpxC inhibitors.
    Dreger A; Hoff K; Agoglitta O; Bülbül EF; Melesina J; Sippl W; Holl R
    Bioorg Chem; 2021 Dec; 117():105403. PubMed ID: 34758434
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Kinetic analysis of the zinc-dependent deacetylase in the lipid A biosynthetic pathway.
    McClerren AL; Zhou P; Guan Z; Raetz CR; Rudolph J
    Biochemistry; 2005 Feb; 44(4):1106-13. PubMed ID: 15667204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.